Showing results (621-630 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|November 4, 2008
Unexpected high rate of wild-type HIV-1 genotype among inmates failing antiretroviral therapyE Pontali, A Ventura, B Bruzzone, et al.
HIV Clinical Trials|February 11, 2009
Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)Esteban Ribera, José Carlos Paradiñeiro, Adria Curran, et al.
HIV Clinical Trials|February 11, 2009
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patientsMarta Boffito, Diego Miralles, Andrew Hill
HIV Clinical Trials|December 17, 2013
Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage studyRodger D Macarthur, Trevor N Hawkins, Stephen J Brown, et al.
HIV Clinical Trials|April 20, 2010
Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA studyAntonio Antela, Antonio Ocampo, Rocío Gómez, et al.
HIV Clinical Trials|April 20, 2010
Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patientsFrank D Goebel, Thomas R MacGregor, John P Sabo, et al.
HIV Clinical Trials|October 27, 2006
Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimenJ Moya, J L Casado, L Aranzabal, et al.
HIV Clinical Trials|July 28, 2009
Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapyJonathan Shuter, Julie A Sarlo, Richard A Rode, et al.
HIV Clinical Trials|July 28, 2009
Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavirM G A van Vonderen, L Gras, F Wit, et al.
HIV Clinical Trials|July 28, 2009
Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adultsLeigh Anne Redhage, Ayumi Shintani, David W Haas, et al.
Pageof 68